Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

602.O1.8 Disordered Gene Expression in Hematologic Malignancy, Including Epigenetic Regulation (I)

Monday, December 8, 2008: 7:00 AM-9:00 AM
Golden Gate Hall (San Francisco Marriott)
Moderators:
Sanne Lugthart, MD and Jacqueline Boultwood
7:00 AM
Haploinsufficiency and Deficiency of a 7q Gene Titan (Samd9L) Predispose Leukemia Development in Cooperation with Deregulated Expression of a Transcription Factor, Evi1, or a Histone Demethylase, Fbxl10

Akiko Nagamachi1*, Hiroya Asou, MD1*, Hirotaka Matsui, MD1*, Yuko Ozaki1*, Daisuke Aki, PhD1*, Kazuko Miyazaki2*, Norimasa Yamasaki2*, Masaki Miyazaki, MD3*, Linda Wolff, PhD4, Richard Koller4*, Hideaki Oda, MD5*, Toshiya Inaba, MD1 and Hiroaki Honda, MD2*

1Department of Molecular Oncology, Research Institute for Radiation Biology & Medicine, Hiroshima University, Hiroshima, Japan
2Department of Developmental Biology, Research Institute for Radiation Biology & Medicine, Hiroshima University, Hiroshima, Japan
3Department of Immunology, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan
4NCI/NIH, Bethesda, MD
5Department of Pathology, Tokyo Women's Medical University, Tokyo, Japan

7:15 AM
PLZF-RARα Utilizes the Histone Methyl Transferase G9a/GLP and the Histone Demethylase LSD1 to Repress RARα Target Genes and Block Myeloid Differentiation

Itsaso Hormaeche, PhD1*, Kim L. Rice, Ph.D.1*, Arthur Zelent, PhD2, Melanie J. McConnell, Ph.D.3 and Jonathan D. Licht, MD1

1Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
2Section of Haemato-Oncology, Institute of Cancer Research, Sutton, England
3Cancer Cell and Molecular Biology, Malaghan Institute of Medical Research, Wellington South, New Zealand

7:30 AM
Knockdown of CCR7 or Its Ligands Causes a Loss of Central Nervous System Involvement in Notch1 Induced T-ALL

Silvia Buonamici1, Thomas Trimarchi1*, Apostolos Klinakis2*, Linsey Reavie1*, Brenton G. Mar3*, Eric Gehrie4*, Emma L. Kuan4*, Gwendalyn J. Randolph4*, Jonathan Bromberg4* and Iannis Aifantis1*

1Pathology, New York University School of Medicine, New York, NY
2Genetics & Development, Columbia University, New York, NY
3Pediatrics, Columbia University Morgan Stanley Children's Hospital of New York Presbyterian, New York, NY
4Gene and Cell Medicine, Mount Sinai School of Medicine, New York, NY

7:45 AM
Chemical Genomic Screen Identifies Ionophores as Modulators of Notch1 in T-ALLClinically Relevant Abstract

Giovanni Roti, MD1*, Kenneth N. Ross, PhD2*, Cristina Mecucci, MD, PhD3, Adolfo A. Ferrando, MD, PhD4, Jon C. Aster, MD, PhD5 and Kimberly Stegmaier, MD6

1Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA
2Cancer Program, The Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, MA
3Hematology, Cytogenetics and Molecular Genetics, Perugia, Italy
4Institute for Cancer Genetics, Columbia University, New York, NY
5Department of Pathology, Brigham and Women's Hospital, Boston, MA
6Pediatric Oncology, Dana-Farber Cancer Institute and The Broad Institute of Harvard University and Massachusetts Institute of Technology, Boston, MA

8:00 AM
Differentiation-Chronology Specific Function of DNMT1 and Selective Anti-Leukemia Stem-Cell Therapy

Soledad Negrotto1*, Zhenbo Hu1*, Kevin A Link2*, Hien Duong1*, Andrew E. Schade, MD, PhD3, Jaroslaw P. Maciejewski, MD, PhD1, James C. Mulloy, PhD2 and Yogenthiran Saunthararajah1

1Experimental Hematology and Hematopoiesis Section, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH
2Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
3Clinical Pathology, Cleveland Clinic, Cleveland, OH

8:15 AM
An Upstream Insulator Element Regulates DLK1 Imprinting in AML

Haytham Khoury, MD1, Fernando Suarez-Saiz1*, Samantha Wu2*, Serban San-Marina1* and Mark Minden1

1Princess Margaret Hospital, Toronto, ON, Canada
2Medical Biophysics, University of Toronto, Toronto, ON, Canada

8:30 AM
The Role of VEGFA in Malignant Progression in AML

Alida C Weidenaar1*, Arja ter Elst2*, Henk-Marijn de Jonge1*, Tiny Meeuwsen-de Boer1*, Willem A Kamps2 and Evelina S De Bont1

1Pediatric Oncology/Hematology, University Medical Center Groningen, Groningen, Netherlands
2Division of Pediatric Oncology/Hematology, Department of Pediatrics,, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen Groningen, Groningen, Netherlands

8:45 AM
Identification of Proteinase 3 (PR3) Gene Overexpresison and Protein Delocalization in Core Binding Factor  Leukemias as a Mechanism Leading to Increased Chemosensitivity.  

Daniela Cilloni, MD, PhD1, Ilaria Defilippi, PhD2*, Sonia Carturan, PhD2*, Chiara Maffč, PhD1*, Marisa Pautasso, MD3*, Ilaria Iacobucci4*, Giovanni Martinelli, MD5*, Emanuela Messa, MD6*, Antonia Rotolo1*, Enrico Bracco, PhD2* and Giuseppe Saglio, MD3

1Dept. Of Clinical and Biological Sciences, University of Turin, Turin, Italy
2Department of Clinical and Biological Sciences, University of Turin, Orbassano,Turin, Italy
3Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
4Department of Hematology and Oncological Sciences "L. e A. Serągnoli", University of Bologna, Bologna, Italy
5Department of Hematology and Oncological Sciences, University of Bologna, Bologna, Italy
6Department of Clinical and Biological Sciences, University of Turin, Orbassano, Turin, Italy

*signifies non-member of ASH